Page last updated: 2024-11-06

stearyltrimethylammonium bromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Stearyltrimethylammonium bromide (CETAB) is a quaternary ammonium cationic surfactant. It is a white, waxy solid that is soluble in water. CETAB is synthesized by the reaction of stearyl alcohol with trimethylamine in the presence of an acid. CETAB has a wide range of applications, including its use as a disinfectant, an emulsifier, and a hair conditioner. It is also used in the manufacture of cosmetics, pharmaceuticals, and industrial products. CETAB is a potent antimicrobial agent that is effective against a wide range of bacteria, fungi, and viruses. It is also a good emulsifier and can be used to create stable emulsions of oil and water. CETAB is a common ingredient in hair conditioners and can help to make hair softer and smoother. CETAB is studied for its effectiveness in treating skin conditions such as acne, eczema, and psoriasis. It is also being investigated for its potential use in the treatment of cancer. CETAB is a safe and effective compound when used as directed. However, it can be irritating to the skin, eyes, and respiratory tract. It is important to handle CETAB with care and to avoid contact with the eyes and skin.'

octadecyltrimethylammonium bromide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID70708
SCHEMBL ID126030
MeSH IDM0312133

Synonyms (44)

Synonym
trimethyloctadecylammonium bromide
trimethyl-octadecyl-ammonium bromide
trimethyl(octadecyl)azanium bromide
FT-0652622
octadecyltrimethylammonium bromide
otab
S0364
trimethylstearylammonium bromide
1120-02-1
stearyltrimethylammonium bromide
A19036
octadecy trimethyl ammonium bromide
stearyltrimethylammonium bromide (stab)
1-octadecanaminium, n,n,n-trimethyl-, bromide
steartrimonium bromide
1-octadecanaminium, n,n,n-trimethyl-, bromide (1:1)
trimethyl-1-octylammonium bromide
bpw1dd4iz8 ,
unii-bpw1dd4iz8
einecs 214-294-5
octmab
AKOS015914890
steartrimonium bromide [inci]
n,n,n-trimethyl-1-octadecanaminium bromide
1-octadecanaminium, n,n,n-trimethyl-, bromi
catinal stb
ammonium, trimethyloctadecyl-, bromide
n,n,n-trimethyloctadecan-1-ammonium bromide
SCHEMBL126030
n,n,n-trimethyloctadecan-1-aminium bromide
W-108661
octadecyl trimethyl ammonium bromide
mfcd00043171
DS-6420
octadecyltrimethylammoniumbromide
AMY13723
CCG-268564
D70373
Q27274803
DTXSID40883652
trimethyl(octadecyl)azanium;bromide
HY-W013158
trimethyloctadecylammonium (bromide)
CS-W013874
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dynamin-1Homo sapiens (human)IC50 (µMol)3.15003.15004.17335.0000AID63727
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
endocytosisDynamin-1Homo sapiens (human)
receptor-mediated endocytosisDynamin-1Homo sapiens (human)
endosome organizationDynamin-1Homo sapiens (human)
modulation of chemical synaptic transmissionDynamin-1Homo sapiens (human)
protein homooligomerizationDynamin-1Homo sapiens (human)
protein homotetramerizationDynamin-1Homo sapiens (human)
regulation of vesicle sizeDynamin-1Homo sapiens (human)
clathrin coat assembly involved in endocytosisDynamin-1Homo sapiens (human)
vesicle scissionDynamin-1Homo sapiens (human)
receptor internalizationDynamin-1Homo sapiens (human)
synaptic vesicle budding from presynaptic endocytic zone membraneDynamin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
RNA bindingDynamin-1Homo sapiens (human)
GTPase activityDynamin-1Homo sapiens (human)
protein bindingDynamin-1Homo sapiens (human)
GTP bindingDynamin-1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingDynamin-1Homo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingDynamin-1Homo sapiens (human)
GDP bindingDynamin-1Homo sapiens (human)
protein kinase bindingDynamin-1Homo sapiens (human)
identical protein bindingDynamin-1Homo sapiens (human)
protein homodimerization activityDynamin-1Homo sapiens (human)
microtubule bindingDynamin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
photoreceptor inner segmentDynamin-1Homo sapiens (human)
plasma membraneDynamin-1Homo sapiens (human)
clathrin-coated pitDynamin-1Homo sapiens (human)
endocytic vesicleDynamin-1Homo sapiens (human)
chromaffin granuleDynamin-1Homo sapiens (human)
cell projectionDynamin-1Homo sapiens (human)
extracellular exosomeDynamin-1Homo sapiens (human)
photoreceptor ribbon synapseDynamin-1Homo sapiens (human)
presynapseDynamin-1Homo sapiens (human)
presynaptic endocytic zone membraneDynamin-1Homo sapiens (human)
glutamatergic synapseDynamin-1Homo sapiens (human)
membrane coatDynamin-1Homo sapiens (human)
plasma membraneDynamin-1Homo sapiens (human)
synapseDynamin-1Homo sapiens (human)
microtubuleDynamin-1Homo sapiens (human)
cytoplasmDynamin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID63727Concentration required against dynamin-1 GTPase activity of sheep brain.2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Long chain amines and long chain ammonium salts as novel inhibitors of dynamin GTPase activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (64.29)29.6817
2010's5 (35.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.56 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]